Keros Therapeutics (NASDAQ:KROS) Price Target Lowered to $41.00 at Scotiabank

Keros Therapeutics (NASDAQ:KROS) had its price target dropped by stock analysts at Scotiabank from $44.00 to $41.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “sector outperform” rating on the stock. Scotiabank’s price objective points to a potential upside of 277.53% from the stock’s previous close.

Other equities analysts have also recently issued research reports about the stock. Wells Fargo & Company upped their target price on shares of Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. HC Wainwright dropped their target price on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Guggenheim downgraded shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, December 16th. BTIG Research cut Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, December 12th. Finally, TD Cowen lowered Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $52.56.

Keros Therapeutics Stock Up 3.2 %

Shares of KROS opened at $10.86 on Thursday. Keros Therapeutics has a twelve month low of $9.77 and a twelve month high of $73.00. The company has a market capitalization of $439.91 million, a P/E ratio of -2.08 and a beta of 1.43. The firm has a 50 day moving average of $37.51 and a 200 day moving average of $47.36.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $0.39 million during the quarter. During the same period in the prior year, the company earned ($1.33) EPS. Keros Therapeutics’s revenue was up 4750.0% on a year-over-year basis. On average, sell-side analysts expect that Keros Therapeutics will post -4.74 EPS for the current year.

Institutional Trading of Keros Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Point72 Asset Management L.P. grew its stake in shares of Keros Therapeutics by 155.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after acquiring an additional 577,220 shares during the period. Alkeon Capital Management LLC raised its stake in Keros Therapeutics by 18.7% during the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock worth $110,194,000 after acquiring an additional 298,694 shares during the period. Parkman Healthcare Partners LLC lifted its holdings in Keros Therapeutics by 112.3% during the third quarter. Parkman Healthcare Partners LLC now owns 421,782 shares of the company’s stock valued at $24,493,000 after purchasing an additional 223,155 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Keros Therapeutics by 814.6% in the third quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company’s stock worth $12,990,000 after purchasing an additional 199,245 shares during the period. Finally, FMR LLC increased its stake in shares of Keros Therapeutics by 3.8% in the third quarter. FMR LLC now owns 4,899,134 shares of the company’s stock worth $284,493,000 after purchasing an additional 179,374 shares in the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.